ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Anlotinib as a maintenance treatment for advanced soft tissue sarcoma after first-line chemotherapy (ALTER-S006) a multicentre, open-label, single-arm, phase 2 trial

Xu, Bushu; Pan, Qiuzhong; Pan, Hua; Li, Haomiao; Li, Xianan; Chen, Jing; Pang, Danmei; Zhang, Baoqing; Weng, Desheng; Peng, Ruiqing; Fang, Meiyu*; Zhang, Xing*电子科技大学; 佛山市第一人民医院; 广东省人民医院; 南方医科大学; 中山大学; 中国科学院研究生院; 中国科学院; 1; i
ECLINICALMEDICINE2023-10DOI: 10.1016/j.eclinm.2023.102240
1被引6阅读
引用收藏
分享

摘要

Background No standard maintenance treatment has been obtained to prolong the response duration of soft tissue sarcoma (STS) after first-line chemotherapy. In this study, we aimed to evaluate the efficacy and safety of anlotinib as a maintenance treatment after chemotherapy in STS.Methods In this multicentre, open-label, single-arm phase 2 trial, patients with advanced STS who achieved partial response or stable disease after first-line anthracycline-based chemotherapy were enrolled between April 2019 and January 2022. All patients received anlotinib as a maintenance treatment. The primary endpoint was progression-free survival (PFS) of anlotinib maintenance treatment. Other endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR) and safety. This study is registered with ClinicalTrials.gov, NCT03890068.Findings At the data cut-off date (August 8, 2022), 49 patients were enrolled, including 17 with liposarcoma (35%) and 15 with leiomyosarcoma (31%). After a median follow-up of 17.1 months (IQR 9.0-27.2), the median PFS from the beginning of maintenance treatment was 9.1 months (95% CI 5.7-12.5), and the median OS was not reached, and the 1-year OS rate for anlotinib maintenance treatment was 98.0%. The best ORR and DCR were 16% (8/49, 95% CI 7-30) and 94% (46/49, 95% CI 83-99), respectively. Most of the treatment-related adverse events were grade 1-2. Of the grade 3-4 adverse events, the most common were hypertension (10%) and hand-foot syndrome reaction (6%).Interpretation Postchemotherapy maintenance treatment with anlotinib exhibits promising efficacy and tolerable toxicity in patients with advanced STS.

学科与关键词

关键词
AnlotinibSoft tissue sarcomaMaintenance treatmentFirst-line chemotherapy
相关
加载中…
  • Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial
    Yu, Wenxi; Zhang, Hongmei; Chen, Jing; Zhang, Xing; Chen, Yong; Qu, Guofan; Huang, Gang; Zhou, Yuhong; Ye, Ting; Fan, Zhengfu*; Yao, Yang*Annals of Translational Medicine, 2022, 10(18): 981.被引 4
  • Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study
    Zhou, Yongjian; Zeng, Chunling; Sun, Xiaofeng; Zhang, Jun; Qu, Hongyan; Zhang, Xinhua; Zhou, Ye; Liu, Zimin; Wu, Xiaojun; Wu, Xin; Jiao, Xuelong; Shen, Lin; Zhou, Yanbing*; Wang, Yuexiang*; Li, Jian*ONCOLOGIST, 2023.
  • The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer
    Wang, Fen*; Jin, Feng; Cheng, Boran; Zhang, Yue; Zhou, Qing; Wang, ShubinJournal of Cancer Research and Clinical Oncology, 2022, 148(7): 1721-1735.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
ECLINICALMEDICINE
发表日期
2023-10
卷期
第 64 卷
页码
102240
DOI
10.1016/j.eclinm.2023.102240
成果收录
SCIE
资助标注
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; National Key Research and Development Program of China; National Natural Science Foundation of China

作者

  • X

    Xu, Bushu (第一作者)

    sun yat sen univ

  • P

    Pan, Qiuzhong

    sun yat sen univ

查看全部 12 位作者收起作者
  • P

    Pan, Hua

    sun yat sen univ

  • L

    Li, Haomiao

    southern med univ

  • L

    Li, Xianan

    hunan canc hosp

  • C

    Chen, Jing

    sichuan canc hosp & inst · univ elect sci & technol china

  • P

    Pang, Danmei

    first peoples hosp foshan

  • Z

    Zhang, Baoqing

    guangdong prov hosp

  • W

    Weng, Desheng

    sun yat sen univ

  • P

    Peng, Ruiqing

    sun yat sen univ

  • F

    Fang, Meiyu (通讯)

    1 · chinese acad sci · i · univ chinese acad sci · zhejiang canc hosp

  • Z

    Zhang, Xing (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417